Wakelee HA, et al. - Researchers sought to assess the addition of bevacizumab to adjuvant chemotherapy in early-stage resected non-small-cell lung cancer (NSCLC). In patients with surgically resected early-stage NSCLC, no improvement in overall survival was observed with the addition of bevacizumab to adjuvant chemotherapy. Thereby suggesting no role of bevacizumab in this setting and thus should not be considered as an adjuvant therapy for these patients.